Sellas Life Sciences is trading 10.39% down at $10.35, with the decline appearing aligned with broader risk-off sentiment ahead of the Federal Reserve decision.
- The stock fell 14.42% on September 11, 2026.
- No fresh company-specific announcement or earnings release was identified for September 14, 2026.
- Major indexes are lower, while the latest company-related coverage concerns previously announced AACR preclinical presentations rather than a new catalyst.